Micardis

DRUG5 trials

Sponsors

Boehringer Ingelheim, Pharmtechnology LLC, Baylor Research Institute

Conditions

BioequivalenceChronic Kidney DiseaseHypertensionMetabolic Syndrome XStrokeType 2 Diabetes

Phase 1

Bioequivalence Study of Two Formulations of Telmisartan 80 mg Tablets in Healthy Adult Volunteers Under Fasting State

CompletedNCT03705533

Pharmtechnology LLCBioequivalence

Start: 2018-09-07End: 2018-12-19Updated: 2018-12-27

Phase 4

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

CompletedNCT00153062

Boehringer IngelheimStroke

Start: 2003-08-31Updated: 2014-05-13

Phase IV, 9 Weeks Comparison Between MICARDIS 80 mg and Amlodipine 10 mg on Biological PPAR Gamma Activities

CompletedNCT00242814

Boehringer IngelheimHypertension, Metabolic Syndrome X

Start: 2005-11-03Updated: 2023-12-08

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Not yet recruitingNCT07547878

Baylor Research InstituteChronic Kidney Disease, Type 2 Diabetes

Start: 2026-04-30End: 2029-03-31Target: 64Updated: 2026-05-08

Unknown Phase

Investigating the Effect of Telmisartan (Micardis®) on the Average 24h Blood Pressure of Therapy-naive and Therapy-experienced Patients

CompletedNCT00879411

Boehringer IngelheimHypertension

Start: 2009-04-30Updated: 2014-03-28

Related Papers

Low Glomerular Filtration Rate, Recurrent Stroke Risk, and Effect of Renin–Angiotensin System Modulation

Stroke2013-08-3032 citations

Telmisartan on top of antihypertensive treatment does not prevent progression of cerebral white matter lesions in the prevention regimen for effectively avoiding second strokes (PRoFESS) MRI substudy.

2012-06-2661 citations

Risk of recurrent stroke in patients with silent brain infarction in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) imaging substudy.

2012-01-1914 citations

Level of systolic blood pressure within the normal range and risk of recurrent stroke.

2011-11-01161 citations

Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study.

2008-08-29219 citations

Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.

2008-08-27573 citations

Telmisartan to prevent recurrent stroke and cardiovascular events.

2008-08-27502 citations